VPS41 Activators
VPS41 Activators encompass a variety of chemical compounds that indirectly enhance the activity of VPS41, a protein pivotal in lysosomal trafficking and endosome-lysosome fusion. These activators primarily function by modulating lysosomal activity and autophagy, processes integral to VPS41's role in the cell. Compounds such as Niclosamide, Bafilomycin A1, Chloroquine, Monensin A, and U 18666A exert their influence by disrupting normal lysosomal function, either by inhibiting acidification or affecting cholesterol transport. This disruption indirectly enhances the role of VPS41 in vesicular trafficking, as the cell compensates for altered lysosomal function. Similarly, autophagy-inducing agents like Rapamycin and Torin 1 indirectly activate VPS41 by promoting autophagic flux, leading to an increased demand for autophagosome-lysosome fusion, a process where VPS41 is critically involved. In contrast, Spautin-1 and LLOMe (L-leucyl-L-leucine methyl ester) inhibit autophagy or disrupt lysosomal integrity, respectively, thereby stimulating VPS41's role in lysosomal repair and recycling.
The secondary impacts of these activators further illustrate the multifaceted role of VPS41 in cellular processes. For instance, Verapamil, by altering intracellular calcium levels, influences vesicular transport and fusion, processes in which VPS41 plays a vital part. Wortmannin, a PI3K inhibitor, modifies endocytic trafficking, consequently affecting VPS41's function in lysosomal fusion. Lastly, Z-VAD-FMK, a pan-caspase inhibitor, preserves cellular integrity during stress conditions, ensuring the continued involvement of VPS41 in essential cellular functions like vesicular trafficking and fusion. Collectively, these activators, through their diverse mechanisms, underscore the significance of VPS41 in maintaining cellular homeostasis. They highlight how altering lysosomal function, autophagic processes, and intracellular signaling pathways can indirectly augment the activity of VPS41, thereby emphasizing its crucial role in vesicular transport and the maintenance of lysosomal health within the cell.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $38.00 $79.00 $188.00 $520.00 $1248.00 $5930.00 | 8 | |
Niclosamide, a known autophagy inhibitor, indirectly enhances VPS41 activity by disrupting autophagic processes. This disruption leads to increased lysosomal function, where VPS41 plays a critical role in vesicular trafficking and fusion. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1, a vacuolar H+-ATPase inhibitor, indirectly activates VPS41 by inhibiting lysosomal acidification. This inhibition leads to enhanced lysosomal trafficking and fusion activities, functions where VPS41 is directly involved. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine, a lysosomotropic agent, indirectly activates VPS41 by raising lysosomal pH. This elevation affects lysosomal function, subsequently enhancing the role of VPS41 in lysosomal trafficking and endosome-lysosome fusion. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin A, an ionophore that disrupts lysosomal pH, indirectly enhances VPS41 activity. By altering lysosomal function, it impacts vesicular trafficking, a process where VPS41 is critically involved. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $143.00 $510.00 | 2 | |
U 18666A, a cholesterol transport inhibitor, indirectly enhances VPS41 activity by disrupting endosomal-lysosomal trafficking. This disruption influences VPS41's role in vesicular transport and fusion within the lysosomal pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor known to induce autophagy, indirectly affects VPS41 by promoting autophagic flux. This increase in autophagic activity indirectly enhances VPS41's function in autophagosome-lysosome fusion. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Spautin-1, an autophagy inhibitor that targets ubiquitin-specific peptidases, indirectly activates VPS41. By inhibiting autophagy, it enhances VPS41-mediated lysosomal fusion and trafficking processes. | ||||||
L-Leucine | 61-90-5 | sc-364173 sc-364173A | 25 g 100 g | $21.00 $62.00 | ||
LLOMe, a lysosomotropic agent, indirectly enhances VPS41 activity by disrupting lysosomal integrity. This leads to increased demand for lysosomal repair and recycling, processes in which VPS41 is vital. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1, an mTOR inhibitor stronger than Rapamycin, indirectly activates VPS41 by inducing autophagy. This activation leads to enhanced autophagosome-lysosome fusion, where VPS41 plays a significant role. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil, a calcium channel blocker, indirectly influences VPS41 activity by altering intracellular calcium levels, which are crucial for vesicular trafficking and fusion, processes where VPS41 is involved. | ||||||